Hoang Hoa Nguyen, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1427589357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 49.5% of the total. Reporting peaked in 2024 at $244 and has fallen 70.7% since, to $71 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IL, where the typical reported total is $2,778.
Across 24 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$318
- Boston Scientific$123
- Octapharma USA, Inc.$52
- Axonics, Inc.$48
- Medtronic$44
- Takeda Pharmaceuticals U.S.A., Inc.$40
- plus $17 from 1 others
What the payments were for
- Food & beverage$642100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $318 |
| Boston Scientific | 2 | $123 |
| Octapharma USA, Inc. | 1 | $52 |
| Axonics, Inc. | 2 | $48 |
| Medtronic | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
How this compares
$642 in reported general payments places this provider in the 15th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 51 | $30,448 |
| MyrbetriqMirabegron | 47 | $22,725 |
| Estradiol | 88 | $5,500 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 141 | $1,456 |
| Cephalexin | 27 | $282 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $76 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Thythy PhamChicago$8K
- Ankita GuptaChicago$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.